$QNRX 8-K SEC Filings

Filed On	Filing
20 Oct 2026	8-K: Regulation FD Disclosure; Other Events Quoin Pharmaceuticals Announces Publication of Peer-Reviewed Paper on QRX003 for Netherton Syndrome in Dermatology and Therapy
14 Oct 2026	8-K: Regulation FD Disclosure; Other Events Quoin Pharmaceuticals Announces European Medicines Agency (EMA) Grants Orphan Drug Designation for QRX003 for the Treatment of Peeling Skin Syndrome
22 Sep 2026	8-K: Regulation FD Disclosure; Other Events First-Ever Fast Track Designation Granted for a Peeling Skin Syndrome Therapy
10 Sep 2026	8-K: Regulation FD Disclosure; Other Events FDA Previously Granted RPD Designation for QRX003 in Netherton Syndrome
28 Aug 2026	8-K: Entry into a Material Definitive Agreement; Unregistered Sales of Equity Securities +2 more
20 Aug 2026	8-K: Departure/Election of Directors or Officers; Compensation; Submission of Matters to a Vote of Security Holders +1 more
14 Aug 2026	8-K: Results of Operations and Financial Condition
23 Jun 2026	8-K: Regulation FD Disclosure; Other Events
04 Jun 2026	8-K: Regulation FD Disclosure; Other Events
07 May 2026	8-K: Results of Operations and Financial Condition
26 Mar 2026	8-K: Results of Operations and Financial Condition
11 Mar 2026	8-K: Regulation FD Disclosure; Other Events
20 Jan 2026	8-K: Regulation FD Disclosure; Other Events
17 Nov 2025	8-K: Departure/Election of Directors or Officers; Compensation
12 Nov 2025	8-K: Regulation FD Disclosure; Other Events
06 Nov 2025	8-K: Results of Operations and Financial Condition
21 Oct 2025	8-K: Regulation FD Disclosure; Other Events
15 Oct 2025	8-K: Entry into a Material Definitive Agreement; Unregistered Sales of Equity Securities +1 more
27 Aug 2025	8-K: Departure/Election of Directors or Officers; Compensation
21 Aug 2025	8-K: Material Modification to Rights of Security Holders; Departure/Election of Directors or Officers; Compensation +3 more

Comments